TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 56.6 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $17.649 million which missed the analyst consensus estimate of $23.166 million by 23.82 percent. This is a 3.83 percent increase over sales of $16.998 million the same period last year.